Insider Purchases: Inside the Buy

Tag: why-buy-xoma

Illustration of a stylized crown hovering above biotech molecules and financial charts, representing XOMA Royalty’s strategy of collecting biotech royalties without developing drugs.

December 9, 2025

Can XOMA Become Royalty? The CEO, BVF Partners, and Morgan Stanley Think So!

XOMA Royalty doesn’t run clinical trials—it collects royalties. With a $2.5M CEO insider buy, heavyweight institutional backing, and improving cash flow, this biotech quiet achiever may be turning into something… royal.

Read entire article

Tags: Biotech Royalties, Biotech Stocks, buy-or-sell-XOMA, CEO buy, CEO Buys, CEO Conviction, CEO insider buying, CEO Insider Purchases, CEO Stock Purchase, CEOBuyIn, CEOConfidence, featured-insiders, funanc1al edge, funanc1al humor, FUNanc1al Investing, FUNstock Income + Growth, Healthcare Investing, hub-diversify, hub-epiphany, hub-fun, hub-hedge, hub-insiders, hub-ipos, hub-overseas, hub-ridiculous, hub-special-files, hub-value, Insider Buying, risks-investing-in-xoma, Royalty Stocks, Small-Cap Stocks, why-buy-xoma, XOMA, XOMA Royalty

Your cart

Insider Purchases: Inside the Buy

Tag: why-buy-xoma

December 9, 2025

Can XOMA Become Royalty? The CEO, BVF Partners, and Morgan Stanley Think So!

Quick links

Contact us

About us

Follow us